Annabel Kartal-Allen on Muck Rack

Annabel Kartal-Allen

Verified
London
As seen in: Clinical Trials Arena, Medical Device Network, Pharmaceutical Technology, MSN, The Guardian, Yahoo Finance, Yahoo, Genetic Literacy Project, Pharmaceutical-Technology.com, Investment Monitor, Nutraceutical Business Review, Manufacturing Chemist, The Badger and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Annabel

Contact Annabel, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Three PsA trials to watch in 2026

|
By Annabel Kartal-Allen Verified
| Yahoo Verified
With the European Alliance of Associations for Rheumatology’s (EULAR) 2026 meeting less than a month away, physicians, researchers and other healthcare professionals are gearing up for a trip to the UK’s capital, where they will absorb the latest developments in diseases like psoriatic arthritis (PsA).
Open in Who Shared View Duplicates (3) Issue with article?

Biogen forges on with Alzheimer’s therapy development despite Phase II miss Original

|
By Annabel Kartal-Allen Verified
| Clinical Trials Arena Verified
Biogen will progress diranersen to a Phase III trial in Alzheimer’s disease. Credit: Jeviredurose_design / Shutterstock.com. Biogen is firing up a registrational programme for its tau-focused Alzheimer’s disease therapy, diranersen, despite the drug missing its primary endpoint in a mid-stage study.
Open in Who Shared View Duplicates (2) Issue with article?

Shionogi weighs future of FXS drug after double Phase III miss

|
By Annabel Kartal-Allen Verified
| MSN Verified
Annabel Kartal Allen Shionogi is mulling over the fate of its fragile X syndrome (FXS) therapy, zatolmilast, after the drug failed to meet its primary endpoints in a duo of Phase IIb/III trials – potentially devaluing the company's $500m takeover of the drug's creator, Tetra Therapeutics, six years ago.
Open in Who Shared Issue with article?
See all 983 licensed articles (1,067 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified